WEKO3
アイテム
{"_buckets": {"deposit": "f5fd1204-3dbc-43ae-b851-1e0107277c11"}, "_deposit": {"created_by": 1, "id": "46410", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "46410"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00046410", "sets": ["1"]}, "author_link": ["462308", "462309", "462311", "462317", "462314", "462316", "462312", "462313", "462315", "462310"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2011-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "28", "bibliographicPageStart": "21", "bibliographicVolumeNumber": "2", "bibliographic_titles": [{"bibliographic_title": "Oncology Letters"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "This study aimed to investigate whether glucose transporter-1 (GLUT-1) expression in a pretreatment esophageal cancer biopsy was predictive of clinical outcomes in patients with esophageal cancer undergoing concurrent chemoradiotherapy (CRT). A total of 25 patients with esophageal cancer treated with concurrent CRT were reviewed. Radiotherapy was administered up to total doses of 40-66.6 Gy (median 66.6 Gy) with a single fraction of 1.8-2 Gy. Regarding chemotherapy, cisplatin (80 mg/m2 on day 1) and 5-fluorouracil (800 mg/m2 on days 2-6) were used concurrently with radiotherapy, every 3-4 weeks for a total of 1-2 courses. Tissue samples from esophageal carcinoma were obtained from the 25 patients by biopsy prior to concurrent CRT, and a semiquantitative analysis of GLUT-1 expression was performed using immunohistochemical staining. High GLUT-1 expression was observed in 7 of 25 (28%) patients, and GLUT-1 expression was significantly correlated with clinical T stage (p=0.0454), clinical N stage (p=0.0324) and initial response to CRT (p=0.0185). Patients with a high GLUT-1 expression had significantly poorer local control (LC) (5-year LC 28.6%) than those with a low expression (5-year LC 73.4%, p\u003c005). Multivariate analysis revealed that GLUT-1 and the number of chemotherapy courses were independent prognostic factors for LC. Patients with a high GLUT-1 expression had significantly lower recurrence-free survival (RFS) compared to those with a low GLUT-1 expression (p=0.0405). Multivariate analysis revealed that GLUT-1, the number of chemotherapy courses and clinical M stage were independent prognostic factors for RFS. GLUT-1 expression was significantly correlated with clinical T stage, clinical N stage and initial response to concurrentCRT, and was predictive of LC and RFS for patients with esophageal cancer treated with concurrent CRT.", "subitem_description_type": "Abstract"}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.3892/ol.2010.199", "subitem_relation_type_select": "DOI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1792-1074", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Chiba, Itaru"}], "nameIdentifiers": [{"nameIdentifier": "462308", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ogawa, Kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "462309", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morioka, Takamitsu"}], "nameIdentifiers": [{"nameIdentifier": "462310", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimoji, Hideaki"}], "nameIdentifiers": [{"nameIdentifier": "462311", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sunagawa, Nao"}], "nameIdentifiers": [{"nameIdentifier": "462312", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Iraha, Shiro"}], "nameIdentifiers": [{"nameIdentifier": "462313", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishimaki, Tadashi"}], "nameIdentifiers": [{"nameIdentifier": "462314", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshimi, Naoki"}], "nameIdentifiers": [{"nameIdentifier": "462315", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Murayama, Sadayuki"}], "nameIdentifiers": [{"nameIdentifier": "462316", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "森岡 孝満", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "462317", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/46410", "pubdate": {"attribute_name": "公開日", "attribute_value": "2012-10-02"}, "publish_date": "2012-10-02", "publish_status": "0", "recid": "46410", "relation": {}, "relation_version_is_last": true, "title": ["Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy"], "weko_shared_id": -1}
Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy
https://repo.qst.go.jp/records/46410
https://repo.qst.go.jp/records/46410abfa5cec-0854-46b7-abee-40a2aec034e7
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2012-10-02 | |||||
タイトル | ||||||
タイトル | Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Chiba, Itaru
× Chiba, Itaru× Ogawa, Kazuhiko× Morioka, Takamitsu× Shimoji, Hideaki× Sunagawa, Nao× Iraha, Shiro× Nishimaki, Tadashi× Yoshimi, Naoki× Murayama, Sadayuki× 森岡 孝満 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | This study aimed to investigate whether glucose transporter-1 (GLUT-1) expression in a pretreatment esophageal cancer biopsy was predictive of clinical outcomes in patients with esophageal cancer undergoing concurrent chemoradiotherapy (CRT). A total of 25 patients with esophageal cancer treated with concurrent CRT were reviewed. Radiotherapy was administered up to total doses of 40-66.6 Gy (median 66.6 Gy) with a single fraction of 1.8-2 Gy. Regarding chemotherapy, cisplatin (80 mg/m2 on day 1) and 5-fluorouracil (800 mg/m2 on days 2-6) were used concurrently with radiotherapy, every 3-4 weeks for a total of 1-2 courses. Tissue samples from esophageal carcinoma were obtained from the 25 patients by biopsy prior to concurrent CRT, and a semiquantitative analysis of GLUT-1 expression was performed using immunohistochemical staining. High GLUT-1 expression was observed in 7 of 25 (28%) patients, and GLUT-1 expression was significantly correlated with clinical T stage (p=0.0454), clinical N stage (p=0.0324) and initial response to CRT (p=0.0185). Patients with a high GLUT-1 expression had significantly poorer local control (LC) (5-year LC 28.6%) than those with a low expression (5-year LC 73.4%, p<005). Multivariate analysis revealed that GLUT-1 and the number of chemotherapy courses were independent prognostic factors for LC. Patients with a high GLUT-1 expression had significantly lower recurrence-free survival (RFS) compared to those with a low GLUT-1 expression (p=0.0405). Multivariate analysis revealed that GLUT-1, the number of chemotherapy courses and clinical M stage were independent prognostic factors for RFS. GLUT-1 expression was significantly correlated with clinical T stage, clinical N stage and initial response to concurrentCRT, and was predictive of LC and RFS for patients with esophageal cancer treated with concurrent CRT. | |||||
書誌情報 |
Oncology Letters 巻 2, 号 1, p. 21-28, 発行日 2011-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1792-1074 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.3892/ol.2010.199 |